[Molecular mechanisms underlying proteinuria reduction and protection of nephrin and podocytes by ARB].
Kumagai
Hiroo
H
Department of Internal Medicine, Keio University School of Medicine.
Onami
Toshiko
T
Takimoto
Chie
C
Iigaya
Kamon
K
Saruta
Takao
T
D000185:Actinin / Q000502:physiology; D000199:Actins / Q000502:physiology; D048868:Adaptor Proteins, Signal Transducing; D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D003598:Cytoskeletal Proteins; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins; D007676:Kidney Failure, Chronic / Q000209:etiology / Q000517:prevention & control; D008565:Membrane Proteins / Q000502:physiology*; D050199:Podocytes / Q000166:cytology / Q000502:physiology*; D011506:Proteins / Q000502:physiology; D011507:Proteinuria / Q000188:drug therapy* / Q000209:etiology*; D044140:Receptor, Angiotensin, Type 1 / Q000378:metabolism; D013777:Tetrazoles / Q000494:pharmacology / Q000627:therapeutic use; D014633:Valine / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D000068756:Valsartan
D000199:Actins; D048868:Adaptor Proteins, Signal Transducing; D047228:Angiotensin II Type 1 Receptor Blockers; C114545:CD2-associated protein; D003598:Cytoskeletal Proteins; D047908:Intracellular Signaling Peptides and Proteins; D008565:Membrane Proteins; C407223:NPHS2 protein; D011506:Proteins; D044140:Receptor, Angiotensin, Type 1; D013777:Tetrazoles; C113267:nephrin; D000185:Actinin; D000068756:Valsartan; D014633:Valine